BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gimeno-valiente F, López-rodas G, Castillo J, Franco L. Alternative Splicing, Epigenetic Modifications and Cancer: A Dangerous Triangle, or a Hopeful One? Cancers 2022;14:560. [DOI: 10.3390/cancers14030560] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ming T, Tao Q, Tang S, Zhao H, Yang H, Liu M, Ren S, Xu H. Curcumin: An epigenetic regulator and its application in cancer. Biomedicine & Pharmacotherapy 2022;156:113956. [DOI: 10.1016/j.biopha.2022.113956] [Reference Citation Analysis]
2 Setlai BP, Mkhize-Kwitshana ZL, Mehrotra R, Mulaudzi TV, Dlamini Z. Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma. Int J Mol Sci 2022;23:8991. [PMID: 36012262 DOI: 10.3390/ijms23168991] [Reference Citation Analysis]
3 De Kesel J, Fijalkowski I, Taylor J, Ntziachristos P. Splicing dysregulation in human hematologic malignancies: beyond splicing mutations. Trends Immunol 2022;43:674-86. [PMID: 35850914 DOI: 10.1016/j.it.2022.06.006] [Reference Citation Analysis]
4 Imbriano C, Belluti S. Histone Marks-Dependent Effect on Alternative Splicing: New Perspectives for Targeted Splicing Modulation in Cancer? IJMS 2022;23:8304. [DOI: 10.3390/ijms23158304] [Reference Citation Analysis]